Zacks Investment Research upgraded shares of Compugen Ltd. (NASDAQ:CGEN) from a sell rating to a hold rating in a report published on Monday.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, FBR & Co set a $14.00 price target on Compugen and gave the stock a buy rating in a report on Friday, May 19th.

Compugen (CGEN) opened at 3.00 on Monday. The company has a 50-day moving average of $3.49 and a 200 day moving average of $4.06. Compugen has a one year low of $2.60 and a one year high of $7.57. The firm’s market cap is $153.39 million.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. Compugen had a negative return on equity of 57.69% and a negative net margin of 4,425.00%. Equities research analysts expect that Compugen will post ($0.73) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Compugen Ltd. (CGEN) Upgraded by Zacks Investment Research to “Hold”” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/29/compugen-ltd-cgen-upgraded-by-zacks-investment-research-to-hold.html.

Hedge funds have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new stake in shares of Compugen during the second quarter valued at $162,000. ARK Investment Management LLC increased its stake in shares of Compugen by 104.1% in the second quarter. ARK Investment Management LLC now owns 560,103 shares of the biotechnology company’s stock valued at $2,128,000 after buying an additional 285,653 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Compugen by 522.2% in the first quarter. Tower Research Capital LLC TRC now owns 23,576 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 19,787 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Compugen by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 59,797 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 16,696 shares during the last quarter. Finally, Raging Capital Management LLC increased its stake in shares of Compugen by 35.3% in the first quarter. Raging Capital Management LLC now owns 4,236,522 shares of the biotechnology company’s stock valued at $18,217,000 after buying an additional 1,104,391 shares during the last quarter. 17.49% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.